77 related articles for article (PubMed ID: 29862508)
1. Equine pituitary pars intermedia dysfunction: current understanding and recommendations from the Australian and New Zealand Equine Endocrine Group.
Secombe CJ; Bailey SR; de Laat MA; Hughes KJ; Stewart AJ; Sonis JM; Tan R
Aust Vet J; 2018 Jul; 96(7):233-242. PubMed ID: 29862508
[TBL] [Abstract][Full Text] [Related]
2. BEVA primary care clinical guidelines: Diagnosis and management of equine pituitary pars intermedia dysfunction.
Menzies-Gow NJ; Banse HE; Duff A; Hart N; Ireland JL; Knowles EJ; McFarlane D; Rendle D
Equine Vet J; 2024 Mar; 56(2):220-242. PubMed ID: 37795557
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis of equine pituitary pars intermedia dysfunction.
Stewart AJ; Ireland JL; Durham AE; McGowan CM
Vet J; 2023; 300-302():106036. PubMed ID: 37805159
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of seasonal influences on adrenocorticotropic hormone response to the thyrotropin-releasing hormone stimulation test and its accuracy for diagnosis of pituitary pars intermedia dysfunction.
Adams AA; Siard-Altman MH; Reedy SE; Barker D; Elzinga S; Sanz MG; Urschel K; Ireland JL
Vet J; 2023; 300-302():106035. PubMed ID: 37802466
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications of imprecise sampling time for 10- and 30-min thyrotropin-releasing hormone stimulation tests in horses.
Vorster DM; Wang W; Kemp KL; Bamford NJ; Bertin FR
Equine Vet J; 2024 Mar; 56(2):291-298. PubMed ID: 37649416
[TBL] [Abstract][Full Text] [Related]
6. Dermatitis, cellulitis, and osteomyelitis caused by
Waitt Wolker LH; Black A; Lee JK
J Vet Diagn Invest; 2024 Mar; 36(2):248-253. PubMed ID: 38462742
[TBL] [Abstract][Full Text] [Related]
7. Factors affecting measurement of basal adrenocorticotropic hormone in adult domestic equids: A scoping review.
Ireland JL; Lester A; Banse HE
Vet J; 2024 Apr; 304():106071. PubMed ID: 38341024
[TBL] [Abstract][Full Text] [Related]
8. Correlation of pituitary histomorphometry with dopamine and dopamine D2 receptor expression in horses with pituitary pars intermedia dysfunction.
Huang L; Palmieri C; Bertin FR
Res Vet Sci; 2022 Dec; 152():427-433. PubMed ID: 36126509
[TBL] [Abstract][Full Text] [Related]
9. Management of pituitary pars intermedia dysfunction in practice: A clinical audit.
Steel NL; Ireland JL; McGowan CM
Vet J; 2022 Nov; 289():105899. PubMed ID: 36162625
[TBL] [Abstract][Full Text] [Related]
10. Retrospective assessment of the use of extended-release cabergoline in the management of equine pituitary pars intermedia dysfunction.
Sundra T; Kelty E; Rossi G; Rendle D
Front Vet Sci; 2024; 11():1332337. PubMed ID: 38511195
[TBL] [Abstract][Full Text] [Related]
11. Medical implications of obesity in horses--lessons for human obesity.
Johnson PJ; Wiedmeyer CE; Messer NT; Ganjam VK
J Diabetes Sci Technol; 2009 Jan; 3(1):163-74. PubMed ID: 20046661
[TBL] [Abstract][Full Text] [Related]
12. Metabolic and Endocrine Insights in Donkeys.
Mendoza FJ; Toribio RE; Perez-Ecija A
Animals (Basel); 2024 Feb; 14(4):. PubMed ID: 38396558
[TBL] [Abstract][Full Text] [Related]
13. Giant leaps forward.
Trainer P
Clin Med (Lond); 2009 Aug; 9(4):363-4. PubMed ID: 19728514
[No Abstract] [Full Text] [Related]
14. Diagnosis of equine endocrine disease special issue.
McGowan C; Ireland J; Carslake H
Vet J; 2024 Jun; ():106177. PubMed ID: 38880228
[No Abstract] [Full Text] [Related]
15. Recommendations from the Australian and New Zealand Equine Endocrine Group and the interpretation of plasma endogenous ACTH concentrations for the diagnosis of pituitary pars intermedia dysfunction (PPID).
McGowan C
Aust Vet J; 2018 Sep; 96(9):317-318. PubMed ID: 30152062
[No Abstract] [Full Text] [Related]
16. Diagnostic Testing for Equine Endocrine Diseases: Confirmation Versus Confusion.
McFarlane D
Vet Clin North Am Equine Pract; 2019 Aug; 35(2):327-338. PubMed ID: 31076223
[TBL] [Abstract][Full Text] [Related]
17. Re: Recommendations from the Australian and New Zealand Equine Endocrine Group and the interpretation of plasma endogenous ACTH concentrations for the diagnosis of pituitary pars intermedia dysfunction (PPID).
Secombe C; Bailey S; de Laat M; Hughes K; Stewart A; Sonis J; Tan R
Aust Vet J; 2018 Sep; 96(9):319. PubMed ID: 30152059
[No Abstract] [Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction.
Rendle DI; Doran G; Ireland J; Edwards S
Domest Anim Endocrinol; 2019 Jul; 68():135-141. PubMed ID: 31082785
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of pergolide for the management of equine pituitary pars intermedia dysfunction: A systematic review.
Tatum RC; McGowan CM; Ireland JL
Vet J; 2020 Dec; 266():105562. PubMed ID: 33323174
[TBL] [Abstract][Full Text] [Related]
20. Pituitary Pars Intermedia Dysfunction and Metabolic Syndrome in Donkeys.
Gehlen H; Schwarz B; Bartmann C; Gernhardt J; Stöckle SD
Animals (Basel); 2020 Dec; 10(12):. PubMed ID: 33302557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
